MYC and colorectal carcinoma: Although the detailed selectivity to c-MYC G4 over the others was not mentioned in the report, the identified compound (Tz 1) allowed for an excellent repression of c-MYC at low micromolar concentrations in cultures of colorectal carcinoma (HCT116) cells, and the G4-mediated action was biologically validated by an exon-specific RT-qPCR assay [93,94] in Burkitt’s lymphoma (CA46) cells (Figure 3b).